Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus Inc. reported a total revenue of $55.5 million in its surgical solutions segment, reflecting a 3.4% increase as reported and a 10.3% growth excluding divestiture impacts, primarily driven by effective commercial strategies and strong sales execution. The pain treatments segment showcased impressive performance with revenues of $79.7 million, and anticipated investments are expected to yield further growth in the latter half of 2026 and beyond. Management projects a low-double-digit percentage growth for the surgical solutions business in 2026 and foresees significant improvement in adjusted EBITDA margins by 200 to 250 basis points between 2025 and 2030, suggesting a positive long-term outlook for the company.

Bears say

Bioventus Inc. is facing a negative outlook due to anticipated elevated investment levels in key growth areas while simultaneously experiencing flat to declining adjusted EBITDA margins for 2026 and 2027 compared to 2025. The company reported a significant decline of 26.0% in restorative therapies revenue, reflecting ongoing challenges in both domestic and international markets, alongside an overall revenue growth of only 5.3%. Additionally, the gross margin decreased to 68.9%, falling short of estimates, which further illustrates the financial pressures impacting Bioventus's profitability.

Bioventus (BVS) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 3 analysts, Bioventus (BVS) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.